Physician profile
Mark R Penaranda
NPI 1639731797
$2,230.10
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $715 · 2023: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $565.50 | 2021-2023 | Xifaxan, Trulance |
| Abbvie INC. | $471.17 | 2021-2023 | |
| Janssen Biotech, INC. | $159.79 | 2021-2023 | Stelara |
| Nestle Healthcare Nutrition INC. | $145.13 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $118.58 | 2022-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $117.26 | 2021-2023 | Entyvio |
| Genzyme Corporation | $115.56 | 2022-2023 | |
| Celgene Corporation | $113.16 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $82.77 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $65.81 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $55.33 | 2022-2023 | Dificid |
| Braintree Laboratories, INC. | $50.98 | 2021-2023 | Sutab |
| Ardelyx, INC. | $44.45 | 2022-2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $27.88 | 2022-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $24.18 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $23.14 | 2022 | |
| Pfizer INC. | $18.94 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.63 | 2022 | |
| Redhill Biopharma INC. | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Penaranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.